The impact of urate-lowering therapy on kidney function (IMPULsKF)

Main Article Content

D.D. Ivanov


The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (CKD) progression measured by estimated glomerular filtration rate and albuminuria in 180 patients with gout (n = 90) and with CKD (n = 90). The main current tasks include: 1) evaluation of serum urate acid (SUA) level most potential preserving kidney function; 2) the new onset of gout attacks depending on SUA level, both in gout and CKD objects; 3) safety and side effects of target and ultra-low SUA levels for evidence-based urate-lowering therapy optimal regime in CKD and non-CKD with gout.

Article Details

How to Cite
Ivanov, D. “The Impact of Urate-Lowering Therapy on Kidney Function (IMPULsKF)”. KIDNEYS, vol. 6, no. 2, June 2017, pp. 91-93, doi:10.22141/2307-1257.6.2.2017.102786.
Cover story


Richette P, Doherty M, Pascual E, et al 2016 updated EULAR evidence-based recommendations for the management of gout Annals of the Rheumatic Diseases. BMJ. Published Online First: 25 July 2016. doi: 10.1136/annrheumdis-2016-209707.

Ivanov DD, Ivanova MD. Febuxostat improves FGR and BP in non-diabetic adults with CKD 2-3: 4 years follow-up. Nephrology dialysis transplantation. 2015 May;30(3):486-7. doi: 10.1093/ndt/gfv191.46.

Ivanov DD. Renin-angiotensin system blockers and renal functional reserve. Is there a limit of renoprotection? Pochki. 2015;4(14):12-5. (In Russian). doi: 10.22141/2307-1257.

Aparasu RR, Bentley JP. Principles of Research Design and Drug Literature Evaluation. Burlington: John and Barlett Learning; 2015. 370 p.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>